Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799863 | 0.83 | MAOB (0.50) | ALDH1A1CYP3A4HPGDMAPK1HSD17B1 | |
| SCHEMBL310878 | 0.83 | MAOB (0.50) | ALDH1A1CYP3A4HPGDMAPK1HSD17B1 | |
| SCHEMBL364307 | 0.80 | CES2 (0.68) | CA9CA14CES2CES1MAOB | |
| SCHEMBL29766689 | 0.80 | CES2 (0.68) | CA9CA14CES2CES1MAOB | |
| SCHEMBL1264408 | 0.80 | CA1 (0.61) | CLK1DYRK1ADYRK1BALDH1A1CYP3A4 | |
| SCHEMBL16520525 | 0.79 | ALDH1A1 (0.55) | CLK1DYRK1ADYRK1BALDH1A1CYP3A4 | |
| SCHEMBL19859386 | 0.78 | CLK1 (0.40) | CLK1DYRK1ADYRK1BHSD17B1HSD17B2 | |
| SCHEMBL765931 | 0.78 | CSNK2A1 (0.45) | ALDH1A1CES2CES1KDM4EMEN1 | |
| SCHEMBL3621421 | 0.78 | MAOB (0.47) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL201365 | 0.78 | CLK1 (0.47) | CLK1DYRK1ADYRK1BALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | NATIONAL SCIENCE FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20180057485-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | US | disclosed |
| EP-3271355-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017006282-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016150785-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | UACA, CRYZ, MAPT | CLK1 3690/4885DYRK1A 3856/4885DYRK1B 3734/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CLK1 415/4885DYRK1A 604/4885DYRK1B 618/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CLK1 415/4885DYRK1A 604/4885DYRK1B 618/4885 |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | CLK1 2646/4885DYRK1A 3561/4885DYRK1B 3659/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | CLK1 1314/4885DYRK1A 2485/4885DYRK1B 3133/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | CLK1 4021/4885DYRK1A 4517/4885DYRK1B 4574/4885 |
| US-20180057485-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | CLK1 4341/4885DYRK1A 4804/4885DYRK1B 4779/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | CLK1 4476/4885DYRK1A 4831/4885DYRK1B 4842/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | CLK1 3867/4885DYRK1A 4492/4885DYRK1B 4545/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CLK1 4434/4885DYRK1A 4130/4885DYRK1B 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.